Title |
Fractures in women treated with raloxifene or alendronate: a retrospective database analysis
|
---|---|
Published in |
BMC Women's Health, March 2013
|
DOI | 10.1186/1472-6874-13-15 |
Pubmed ID | |
Authors |
Shonda A Foster, Nianwen Shi, Suellen Curkendall, John Stock, Bong-Chul Chu, Russel Burge, David R Diakun, John H Krege |
Abstract |
Raloxifene and alendronate are anti-resorptive therapies approved for the prevention and treatment of postmenopausal osteoporosis. Raloxifene is also indicated to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk of invasive breast cancer. A definitive study comparing the fracture effectiveness and rate of breast cancer for raloxifene and alendronate has not been published. The purpose of this retrospective cohort study was to evaluate fracture and breast cancer rates among patients treated with raloxifene or alendronate. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 50% |
Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Japan | 1 | 3% |
Unknown | 30 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Doctoral Student | 4 | 13% |
Student > Bachelor | 4 | 13% |
Student > Ph. D. Student | 3 | 10% |
Researcher | 2 | 6% |
Student > Postgraduate | 2 | 6% |
Other | 7 | 23% |
Unknown | 9 | 29% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 10 | 32% |
Nursing and Health Professions | 5 | 16% |
Agricultural and Biological Sciences | 3 | 10% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
Earth and Planetary Sciences | 1 | 3% |
Other | 0 | 0% |
Unknown | 10 | 32% |